Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Dystrophinopathy

NCT01826487 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT01826487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01826487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Dystrophinopathy
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2013
Completion date
August 20, 2015
Enrollment
230 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

genetic diseases, inborn, genetic diseases, x-linked, muscular diseases, muscular disorders, atrophic, muscular dystrophies, muscular dystrophy, duchenne, musculoskeletal diseases, nervous system diseases, neuromuscular diseases